Protagonist Therapeutics, Inc
ICOTYDE
moderate-to-severe plaque psoriasis
Resolved
111days ago
Approval decision · Mar 18, 2026
What's at stake
A final FDA approval decision on ICOTYDE for moderate-to-severe plaque psoriasis is expected Mar 18, 2026.
Primary source
· SEC 8-K
verified 16h ago
“On March 18, Protagonist announced that Johnson & Johnson received U.S. Food and Drug Administration approval for ICOTYDE for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older wh”